According to DRG epidemiology, more than 35 million people in the United States suffer migraines. Migraine prophylaxis, though underused, is a core treatment approach to reduce migraine frequency, severity, and duration. Prescription options include a diverse mix of on- and off-label oral drugs, as well as Allergan’s Botox, approved specifically for chronic migraine. Prophylaxis is both individualized and dynamic as physicians adjust regimens to improve outcomes or avoid side effects. Understanding this patient journey provides needed context for new and existing players as next-generation preventives race to market.
Questions Answered
Product Description
Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand use across different lines of therapy using real-world patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing their brand share.
Markets covered: United States
Real-world data: Longitudinal patient-level claims data analysis
Key drugs: Botox, topiramate IR, Trokeni XR, Qudexy XR, topiramate XR, propranolol, amitriptyline, verapamil, others
Key analysis provided: